tetano
Editor, Senior Moderator
Pharmacol Res Perspect
. 2023 Feb;11(1):e01039.
doi: 10.1002/prp2.1039.
The effect of Fingolimod on patients with moderate to severe COVID-19
Soheil Teymouri[SUP] 1 [/SUP], Siamak Pourbayram Kaleybar[SUP] 2 3 [/SUP], Seyyed Sina Hejazian[SUP] 3 [/SUP], Seyyedeh Mina Hejazian[SUP] 3 [/SUP], Khalil Ansarin[SUP] 1 [/SUP], Mohammadreza Ardalan[SUP] 2 [/SUP], Sepideh Zununi Vahed[SUP] 2 [/SUP]
Affiliations
Abstract
Hyper-inflammation, cytokine storm, and recruitment of immune cells lead to uncontrollable endothelial cell damage in patients with coronavirus disease 2019 (COVID-19). Sphingosine 1-phosphate (S1P) signaling is needed for endothelial integrity and its decreased serum level is a predictor of clinical severity in COVID-19. In this clinical trial, the effect of Fingolimod, an agonist of S1P, was evaluated on patients with COVID-19. Forty patients with moderate to severe COVID-19 were enrolled and divided into two groups including (1) the control group (n = 21) receiving the national standard regimen for COVID-19 patients and (2) the intervention group (n = 19) that prescribed daily Fingolimod (0.5 mg) for 3 days besides receiving the standard national regimen for COVID-19. The hospitalization period, re-admission rate, intensive care unit (ICU) administration, need for mechanical ventilation, and mortality rate were assessed as primary outcomes in both groups. The results showed that re-admission was significantly decreased in COVID-19 patients who received Fingolimod compared to the controls (p = .04). In addition, the hemoglobin levels of the COVID-19 patients in the intervention group were increased compared to the controls (p = .018). However, no significant differences were found regarding the intubation or mortality rate between the groups (p > .05). Fingolimod could significantly reduce the re-admission rate after hospitalization with COVID-19. Fingolimod may not enhance patients' outcomes with moderate COVID-19. It is necessary to examine these findings in a larger cohort of patients with severe to critical COVID-19.
Keywords: COVID-19; Fingolimod; cytokine storm; sphingosine 1-phosphate.
. 2023 Feb;11(1):e01039.
doi: 10.1002/prp2.1039.
The effect of Fingolimod on patients with moderate to severe COVID-19
Soheil Teymouri[SUP] 1 [/SUP], Siamak Pourbayram Kaleybar[SUP] 2 3 [/SUP], Seyyed Sina Hejazian[SUP] 3 [/SUP], Seyyedeh Mina Hejazian[SUP] 3 [/SUP], Khalil Ansarin[SUP] 1 [/SUP], Mohammadreza Ardalan[SUP] 2 [/SUP], Sepideh Zununi Vahed[SUP] 2 [/SUP]
Affiliations
- PMID: 36567519
- DOI: 10.1002/prp2.1039
Abstract
Hyper-inflammation, cytokine storm, and recruitment of immune cells lead to uncontrollable endothelial cell damage in patients with coronavirus disease 2019 (COVID-19). Sphingosine 1-phosphate (S1P) signaling is needed for endothelial integrity and its decreased serum level is a predictor of clinical severity in COVID-19. In this clinical trial, the effect of Fingolimod, an agonist of S1P, was evaluated on patients with COVID-19. Forty patients with moderate to severe COVID-19 were enrolled and divided into two groups including (1) the control group (n = 21) receiving the national standard regimen for COVID-19 patients and (2) the intervention group (n = 19) that prescribed daily Fingolimod (0.5 mg) for 3 days besides receiving the standard national regimen for COVID-19. The hospitalization period, re-admission rate, intensive care unit (ICU) administration, need for mechanical ventilation, and mortality rate were assessed as primary outcomes in both groups. The results showed that re-admission was significantly decreased in COVID-19 patients who received Fingolimod compared to the controls (p = .04). In addition, the hemoglobin levels of the COVID-19 patients in the intervention group were increased compared to the controls (p = .018). However, no significant differences were found regarding the intubation or mortality rate between the groups (p > .05). Fingolimod could significantly reduce the re-admission rate after hospitalization with COVID-19. Fingolimod may not enhance patients' outcomes with moderate COVID-19. It is necessary to examine these findings in a larger cohort of patients with severe to critical COVID-19.
Keywords: COVID-19; Fingolimod; cytokine storm; sphingosine 1-phosphate.